Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims. Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Labeling negotiator can defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims in a Pharma & Life Sciences challenge. 2. Labeling negotiator cannot defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues; Pause the pathway is what the extract actually supports after a site-change that invalidates stability claims. 3. A site-change that invalidates stability claims never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close to drop a secondary. 4. Two facts in phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims conflict for labeling negotiator; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for labeling negotiator - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study - What changes to drop a secondary if a site-change that invalidates stability claims is later withdrawn